A detailed history of Private Advisor Group, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Private Advisor Group, LLC holds 254,256 shares of BMY stock, worth $14.7 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
254,256
Previous 264,845 4.0%
Holding current value
$14.7 Million
Previous $11 Million 19.62%
% of portfolio
0.08%
Previous 0.07%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

SELL
$39.66 - $51.75 $419,959 - $547,980
-10,589 Reduced 4.0%
254,256 $13.2 Million
Q2 2024

Aug 05, 2024

SELL
$40.25 - $52.99 $241,620 - $318,098
-6,003 Reduced 2.22%
264,845 $11 Million
Q1 2024

Apr 30, 2024

BUY
$47.98 - $54.4 $289,799 - $328,576
6,040 Added 2.28%
270,848 $14.7 Million
Q4 2023

Feb 06, 2024

SELL
$48.48 - $57.85 $638,724 - $762,173
-13,175 Reduced 4.74%
264,808 $13.6 Million
Q3 2023

Nov 02, 2023

SELL
$57.89 - $64.73 $475,045 - $531,174
-8,206 Reduced 2.87%
277,983 $16.1 Million
Q2 2023

Aug 09, 2023

SELL
$63.71 - $70.74 $585,303 - $649,888
-9,187 Reduced 3.11%
286,189 $18.3 Million
Q1 2023

May 10, 2023

SELL
$65.71 - $74.53 $493,153 - $559,347
-7,505 Reduced 2.48%
295,376 $20.5 Million
Q4 2022

Jan 18, 2023

BUY
$68.48 - $81.09 $516,407 - $611,499
7,541 Added 2.55%
302,881 $0
Q3 2022

Oct 14, 2022

SELL
$0.13 - $76.84 $4,512 - $2.67 Million
-34,715 Reduced 10.52%
295,340 $21 Million
Q2 2022

Jul 13, 2022

SELL
$72.62 - $79.98 $6,172 - $6,798
-85 Reduced 0.03%
330,055 $25.4 Million
Q1 2022

May 12, 2022

SELL
$61.48 - $73.72 $134,087 - $160,783
-2,181 Reduced 0.66%
330,140 $24.1 Million
Q4 2021

Feb 10, 2022

SELL
$53.63 - $62.52 $11.1 Million - $12.9 Million
-206,907 Reduced 38.37%
332,321 $20.7 Million
Q3 2021

Oct 14, 2021

BUY
$59.17 - $69.31 $11.4 Million - $13.3 Million
191,843 Added 55.22%
539,228 $31.9 Million
Q2 2021

Aug 12, 2021

SELL
$61.91 - $67.42 $2.57 Million - $2.8 Million
-41,475 Reduced 10.67%
347,385 $23.2 Million
Q1 2021

Apr 22, 2021

SELL
$59.34 - $66.74 $2.38 Million - $2.67 Million
-40,028 Reduced 9.33%
388,860 $24.5 Million
Q4 2020

Apr 01, 2021

BUY
$57.74 - $65.43 $3.52 Million - $3.99 Million
60,935 Added 16.56%
428,888 $26.6 Million
Q3 2020

Nov 02, 2020

BUY
$57.43 - $63.64 $146,618 - $162,472
2,553 Added 0.7%
367,953 $22 Million
Q2 2020

Aug 17, 2020

BUY
$54.82 - $64.09 $1.11 Million - $1.3 Million
20,334 Added 5.89%
365,400 $21.5 Million
Q1 2020

May 12, 2020

SELL
$46.4 - $67.43 $19,024 - $27,646
-410 Reduced 0.12%
345,066 $19.2 Million
Q4 2019

Feb 10, 2020

BUY
$49.21 - $64.19 $7.72 Million - $10.1 Million
156,869 Added 83.17%
345,476 $22.2 Million
Q3 2019

Nov 13, 2019

BUY
$42.77 - $50.71 $1.02 Million - $1.21 Million
23,859 Added 14.48%
188,607 $9.71 Million
Q2 2019

Aug 14, 2019

BUY
$44.62 - $49.34 $402,918 - $445,540
9,030 Added 5.8%
164,748 $7.47 Million
Q1 2019

May 13, 2019

SELL
$45.12 - $53.8 $172,944 - $206,215
-3,833 Reduced 2.4%
155,718 $7.48 Million
Q4 2018

Feb 11, 2019

SELL
$48.76 - $63.23 $583,510 - $756,673
-11,967 Reduced 6.98%
159,551 $8.29 Million
Q3 2018

Nov 01, 2018

SELL
$55.19 - $62.25 $244,933 - $276,265
-4,438 Reduced 2.52%
171,518 $10.6 Million
Q2 2018

Aug 09, 2018

BUY
$50.53 - $62.98 $3.12 Million - $3.89 Million
61,730 Added 54.04%
175,956 $9.72 Million
Q1 2018

May 09, 2018

SELL
$59.92 - $68.98 $843,134 - $970,617
-14,071 Reduced 10.97%
114,226 $7.23 Million
Q4 2017

Feb 07, 2018

SELL
$59.94 - $65.35 $6.17 Million - $6.73 Million
-102,988 Reduced 44.53%
128,297 $7.94 Million
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $705,397 - $814,087
12,772 Added 5.84%
231,285 $14.8 Million
Q2 2017

Aug 10, 2017

BUY
N/A
218,513
218,513 $12.2 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Private Advisor Group, LLC Portfolio

Follow Private Advisor Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Advisor Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Advisor Group, LLC with notifications on news.